Guggenheim has reiterated a Buy rating on Oracle (NYSE:ORCL) and maintained a $400.00 price target, naming the software and cloud company its "Best Idea" for the run-up to 2026. The firm is recommending investors consider the stock as a long-term opportunity even while Oracle shares trade well below that target.
Oracle's shares are currently trading at $164.58, a level that Guggenheim and third-party fair-value estimates view as materially below the analyst price objective. The market is pricing Oracle at a trailing price-to-earnings ratio of 30.7 despite the company reporting $61 billion in revenue and 11.1% revenue growth over the last twelve months.
Central to Guggenheim's constructive view is Oracle's announced financing plan. The company has said it will seek to raise $45-50 billion in gross proceeds in 2026 to fund an accelerated expansion of Oracle Cloud Infrastructure - OCI - targeted at several key customers, including AMD, Meta, Nvidia, OpenAI, TikTok, and xAI. The scale of the raise and the explicit linkage to OCI build-out frame the firm's outlook.
Oracle management previously reiterated a commitment to preserving an investment-grade debt rating during its fiscal second-quarter 2026 earnings call in December. Nonetheless, investor concern has continued to center on the capital intensity of Oracle's cloud and AI infrastructure initiatives.
Guggenheim believes the company's stated financing framework should reduce uncertainty by clarifying both the timing and the likely magnitude of debt issuance. The research note highlights that it is "encouraging that Oracle is already calling it investment-grade debt," a point the analyst firm thinks should reassure more risk-sensitive holders.
From Guggenheim's perspective, the combination of near-term financing and multi-year growth in OCI presents an opportunity for investors with longer holding periods. The firm describes Oracle as a "decade stock" and projects that the business metrics should become "irrefutable" in roughly five years, signaling a conviction that patient shareholders could be rewarded as infrastructure investments mature.
Other analyst and corporate developments reinforce the focus on cloud and AI expansion. Jefferies has also reiterated a Buy rating on Oracle and maintained a $400 price target. Separately, Oracle won an $88 million contract to provide cloud services for the U.S. Air Force's Cloud One program. The company has introduced an AI-powered life sciences research platform that combines healthcare data with generative AI to support pharmaceutical and medical device customers. Oracle's OPERA Cloud has also been approved by IHG Hotels & Resorts as a property management system option for its global portfolio.
Despite these strategic moves, Oracle's share price has suffered, falling more than 50% from its peak as investor enthusiasm for artificial intelligence cooled. That decline, together with ongoing questions about how the company will finance rapid infrastructure expansion, underpins the divergence between analyst targets and current market pricing.
The balance of analyst endorsements, substantial planned capital raises, and large government and commercial wins frame Oracle's near-term outlook as one driven by heavy investment and long-term positioning in cloud and AI infrastructure. For investors focused on cash flow durability and balance sheet risk, the upcoming financing program and its treatment as investment-grade debt will be central to reassessing Oracle's risk-reward profile.